How to differentiate hyperparathyroid patients among intermittent hypercalcemic urinary stone formers: a combined use of immunoreactive parathyroid hormone and nephrogenous adenosine 3',5'-monophosphate.
D000249:Adenosine Monophosphate / Q000097:blood*; D000328:Adult; D002118:Calcium / Q000494:pharmacology; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000150:complications / Q000175:diagnosis* / Q000503:physiopathology; D006961:Hyperparathyroidism / Q000150:complications / Q000175:diagnosis* / Q000503:physiopathology; D007669:Kidney Calculi / Q000209:etiology* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010280:Parathyroid Glands / Q000503:physiopathology; D010281:Parathyroid Hormone / Q000097:blood* / Q000276:immunology; D013997:Time Factors
D010281:Parathyroid Hormone; D000249:Adenosine Monophosphate; D002118:Calcium